ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1579017
Prognostic Alternative mRNA Splicing in Lung Adenocarcinoma
Provisionally accepted
- Henan University of Science and Technology, Luoyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Alternative splicing (AS) of mRNA has emerged as a promising biomarker for various tumors, playing a crucial role throughout nearly all stages of tumor progression and influencing the tumor immune microenvironment (TIME). Our study was designed to develop an AS-based signature for accurate prognosis prediction in lung adenocarcinoma (LUAD) patients, to delineate the associated immune cell landscape, and to pinpoint promising drug targets.Methods: Prognostic alternative splicing events (PASEs) were identified through univariate Cox regression analysis of RNA-Seq data from The Cancer Genome Atlas (TCGA). These PASEs were incorporated into a least absolute shrinkage and selection operator (LASSO)-Cox proportional hazards model to develop a prognostic signature. Experimental validation was performed using reverse transcription quantitative polymerase chain reaction (RT-qPCR), immunohistochemistry (IHC), and functional assays in vitro and in vivo.Results: A total of 13 PASEs were selected to form the prognostic signature, which demonstrated excellent predictive power for 1-, 2-, and 3-year overall survival, with AUCs of 0.776, 0.751, and 0.767, respectively. High-risk patients, identified by the signature, showed significantly decreased stromal, immune, and combined scores, increased tumor purity (P < 0.001), a reduced prevalence of various immune cell types, diminished immune cell activity, and decreased expression of immune checkpoint genes. Notably, elevated expression of cyclin-dependent kinase inhibitor 2A (CDKN2A), a gene associated with PASEs, correlated with poorer overall survival (OS) and significantly higher infiltration of CD8+ T cells, activated memory CD4+ T cells, and M1 macrophages compared to patients with lower expression. Further validation studies confirmed increased CDKN2A levels in LUAD tissues, with CDKN2A protein expression inversely correlated with LUAD prognosis (HR [hazard ratio] = 2.737, 95%CI [confidence interval]: 1.524-4.915, P=0.0002). CDKN2A was found to promote LUAD progression in vitro. Molecular docking identified YM-201636 and VE-822 (Berzosertib) as potential drugs targeting CDKN2A, both showing promise for LUAD treatment in vivo.Conclusion: PASEs constitute a comprehensive biomarker for predicting prognosis and monitoring the TIME in LUAD patients. Specifically, CDKN2A stands out as a potential prognostic biomarker and drug target for LUAD.
Keywords: Alternative Splicing, Lung Adenocarcinoma, prognosis, Risk model, therapy
Received: 18 Feb 2025; Accepted: 22 May 2025.
Copyright: © 2025 Su, Xu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Panke Su, Henan University of Science and Technology, Luoyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.